• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A compound of the formula: <IMAGE> wherein R1 is lower alkyl, R2 is carboxy or a protected carboxy group, R4 is hydrogen or lower alkyl and Y is a residue of an acid, or a salt.
    公开号:SU856387A3
    申请号:SU772499562
    申请日:1977-06-27
    公开日:1981-08-15
    发明作者:Камия Такаси；Такая Такао；Терадзи Цутоми；Хасимото Масаси；Накагити Осаму；Оку Теруо
    申请人:Фудзисава Фармасьютикал Ко., Лтд (Фирма)；
    IPC主号:
    专利说明:

    (54) A process of producing 2-alkyl 7-acylamido-3-cephem-4-carboxylic acids or their tOLEY invention relates to new radiation Pe tsefsshosporinov derivatives which are biologically active and are useful in medicine as antibiotics. A known method for the preparation of 3-substituted 7-acylamido-3-cephem-4-carCiuic acids or their salts with an acyl amide, respectively, of the W-substituted 7-gNo-3-cephem-4-carboxylic acid or its reactive derivative of fl: / Purpose of the invention: obtaining new cephalosTeporin derivatives containing an alkyl substituent in position 15 2 and not yet in position 3, expanding the degree of impact on a living organism. This goal is achieved by a process for the preparation of 2-lower alkyl-7-20-acylamido-3-cephem-4-carboxylic acid derivatives of the formula N-jT-A -BONH-I PY rAdJ g. R is methyl or methyl; R is a hydrogen atom, trihalo (lower) alkyl, lower al- 30 yl, wha where it is below where silt is addo-canyloxy (lower) alkyl or p-nitrobenzene-J, hydrogen, lower alkanoyl or trihalo- (lower) alkanoyl; carbonyl, hydroxymethylene, synoxyiminomethylene or syn-lower alkoxyiminomethylene, or in the case R or R is a hydrogen atom, x salts, consisting of the compound of the formula NgTG-h-l V oJ-N; U and RO- have the abovementioned sign, or its metal salt, R is a hydrogen atom, and an acid additive salt, reacts with the compound. A-bun N-ip ngL; and A have the indicated values, with its metal or acid salt in the organic solvent medium in the presence of a halogenating agent at pH 4-10 with cooling or at room temperature, and select the desired product as the free acid, ester or salt.
    The desired compounds of the formula D and the starting compounds of the formula I may exist as taumers due to the presence of a thiazolyl moiety.
    -G TT
     - j {3jjX J
    BMN
    which easily go from one form to another.
     The group R3 protecting the amino group can be removed by hydrolysis or reduction.
    The ester group COOR can be converted to a carboxyl group also by hydrolysis or reduction by g, then the free acid can be converted to salt.
    The target compounds (I) and their pharmaceutically acceptable salts have high antibacterial activity and inhibit the growth of a whole range of microorganisms, including gram-positive and gram-negative bacteria. For therapeutic purposes, the compounds obtained by the method of this invention can be used in the form of pharmaceutical preparations containing these compounds as active ingredient, mixed with pharmaceutically acceptable excipients, in the form of solid organic and inorganic additives or liquid d bavok suitable for oral, parenteral or topical administration. Pharmaceutical preparations can be in the form of capsules, tablets, dragees, ointments, suppositories, solutions, suspensions, emulsions, etc. If desired, additional substances, stabilizing agents, wetting or emulsifying agents, buffering compounds and other commonly used additives may be included in these preparations.
    The course of the dosage of the compounds varies depending on the age and condition of the patient, the average dose per dose is about 10.50, 100, 250, 500 and 1000 mg to effectively combat infectious diseases caused by pathogenic bacteria.
    The structure of all the products obtained was confirmed by NMR and IR spectra.
    Getting the original compounds.
    Example 1, A. A mixture of hydrochloride 2,2,2-trichloroethyl 2-methyl-7-amino-3-cephem-4-carboxylate (0.38 g of trimethylsilylacetamide (1.1 g; methylene chloride (10 ml)) . Sewn for 30 minutes at room temperature and the solution thus prepared is cooled to. To the solution
    methyl 3-oxo-4-bromobutyryl (1.0 mmol) in carbon tetrachloride (13 ml) is added dropwise with cooling to -15 ° C, and the resulting mixture is stirred for 1.5 hours at the same temperature for 30 minutes without addition who is cooling The mixture was poured into cold water and then the organic layer was separated. The organic layer is washed with 2N. hydrochloric acid (13X8 ml) and water (2-10 ml), dried over magnesium sulfate and then filtered. The filtrate is concentrated under reduced pressure. The resulting residue is pulverized in diisopropyl ether, isolated by filtration and dried. Get
    5 light brown powder 2,2,2-trichloroethyl 2-methyl-7- (3-oxo-4-bromobutyramino) -3-cephem-4-carboxylate 0.31 g, m.p. 78-83 ° C (with decomposition).
    Q In the same way, n-nitro-benzene J 2-methyl-7- (3-oxo-4-bromobutyramido) -3-cephem-4-carboxylate is obtained as a powder.
    IR (nujol): 3270, 1780, 1725, 1655, 162S, 1600 cm.
    . B. To a solution of 2, 2,2-trichloroethyl 2-methyl-7- (3-oxo-4-bromobutyramido) -3-cephem-4-carboxylate (2.54 g) in glacial acetic acid (25 ml) was added sodium solution is dropped by drop
    0 nitrite hydrate (0.33 n.) In water (1 ml) for 3 min with stirring, at 1015 ° C, and then the resulting mixture was stirred for 1 h at the same temperature. After that, the reaction mixture
    5 was poured into cold water (70 ml), the precipitate was collected by filtration and dried. A brown powder of 2,2,2-trichloroethyl 2-methyl-7- (2-oximino-3-oxo-4. -Bromobutyramino) 3-cephem0 -4-carboxylate (mixture of syn- and anti-antisera) (2.0 g) is obtained. m.p. 7b-80 ° C (with decomposition).
    P-nitrobenzyl 2-methyl-7- (2-oxyimino-3-oxo-4-bromo-butyramido} -3-cephem-4-carboxylate
    5 (syn-isomer).
    Example 2. To a solution of 2,2,2-trichloroethyl 2-methyl-7- (2-oxyimino-3-oxo-4-bromobutyramido) -3-cephem-40 carboxylate (mixture of syn- and anti-eomers) (1,2 d) in ethanol (20 ml) a solution of diazomethane (0.1 mol) in diethyl ether is added dropwise at. stirring and cooling with ice
    5 to complete the reaction. After the reaction mixture was concentrated under reduced pressure, the residue was pulverized in diisopropyl ether, isolated by filtration and then dried. A brown powder of 2,2,2-trichloroethyl 2-methyl-7- (2-methoxymino-3-oxo-4-bromobutyramido) -3-cephem-4-carboxylate (mixture of syn- and anti-isomers) (1.1 g), so pl. 80f 83 ° C (with decomposition). )
    Example 3. A. To acetic anhydride (384 gl) formic acid (169.2 ml) is added dropwise over a period of 15-20 minutes while cooling below 35 ° C and the resulting mixture is stirred for 1 hour at 55-60 ° C . Ethyl 2- (2-aminothiaool-4-yl) acetate is added to the mixture, which can be presented as ethyl 2- (2-imino-2,3-dihydrothiazol-4-yl) acetate (506 g) over a period of time 15-20 min with ice cooling and stirring, and then the mixture is stirred for 1 h at room temperature. After completion of the reaction, the solvents were distilled off, diisopropyl ether (2500 mi) was added to the resulting residue, and the mixture was stirred for 1 hour at room temperature. The precipitate is isolated by filtration, washed with diisopropyl ether and dried. Ethyl 2- (2-forymylaminothiazol-4-yl) acetate is obtained, which can be represented as ethyl (2-formylimino-2, 3-dihydrothiazol-4-yl) acetate (4.51.6 g), m.p. 125-126 s. The remaining filtrate is concentrated, the residue is washed with diisopropyl ether (500 ml) and dried. Get the same connection (78.5 g)
    B. A mixture of magnesium acetate tetrahydrate (120 g), acetic acid (1000 ml) and acetic anhydride (100 ml) is stirred for 20 minutes in an oil bath heated from 130 to 135 s. Potassium permanganate (20 g) is added to the mixture. 5 minutes at 105-110 ° C and stirring, and the mixture is stirred for another 30 minutes at 130-135 s. The mixture is cooled to room temperature, ethyl 2- (2-formylaminothiazol-4-yl) acetate is added, which can be represented as ethyl 2- (2-formylimino-2, 3-dihydrothiazol-4-yl) acetate (53.5 g ), then the mixture is stirred for 15 hours at 38–40 ° C with air supply at a rate of 6000 ml per minute. After completion of the reaction, the precipitate is isolated by filtration, the isolated precipitate is washed with acetic acid and water successively and then dried. Ethyl 2- (2-formylaminothiazol-4-yl) glyoxylate is obtained, which can be represented as ethyl 2- (2-FORMILIMINO-2,3-dihydro-thiazol-4-yl) glyoxylate (41.5 g), m.p. 232-233s (with decomposition).
    B. To a suspension of ethyl 2- (2-formatylacetaminothiazol-4-yl) glyoxylate, which can be represented as ethyl 2- (formylimino-2,3-dihydrothiazol-4-yl) glyoxylate (281 g), in water (1100 ml) 1 and an aqueous solution of sodium hydroxide (2.23 L) is added with stirring and ice-cooling, and the mixture is stirred for 5 minutes at 10-15 ° C. The reaction mixture is then filtered and the filtrate is adjusted to pH 1 with concentrated hydrochloric acid with stirring. The precipitate is filtered, washed with water and dried. Get 2- (2-formylaminothiazol-4-yl) gloxyl acid, which can be represented as 2- (2-formyl-2,3-dihydro-thiazol-4-yl) glyoxylic acid (234 g), mp. 133- 136 ° С (with decomposition). Example 4. To a suspension of 2- (2-formyl-aminothiazol-4-yl) glyoxylic acid, which can be represented as 2- (2-formylimino-2,3-dihydrothiazol-4-yl) glyoxylic acid (20 g), in water ( 400 ml) was added sodium bicarbonate (8.4 g) while cooling with ice and stirring, then the mixture was stirred for 10 minutes at the same temperature and 10 ml of ethanol was added to it. Sodium borohydride (1.52 g) is added to the resulting mixture over 10 minutes while stirring at the same temperature, and then the mixture is stirred at the same temperature for another 1 hour and 50 minutes. After completion of the reaction, the filtrate mixture was adjusted, the pH of the filtrate was adjusted to 1.0 with 10% hydrochloric acid, then concentrated under reduced pressure to a volume of 100 ml, the pH of the concentrated filtrate was adjusted to 1.0 with 10% hydrochloric acid and induced crystallization by shaking. The concentrated filtrate is stirred for 1 hour at room temperature and left in the refrigerator overnight. The precipitate was filtered, washed twice with ice water and dried with suction. Get 2-hydroxy-2- (2-formylaminothiazol-4-yl) -acetic acid, which. can be represented as 2-hydroxy-2- (2-FORMILIMINO-2, 3-dihydrothiazol-4-yl) acetic acid (14.8 g), so pl. 188-189 p. (with decomposition).
    "
    Example 5.A. Solution of ethyl 2-methoxyimino-4-bromoacetate
    (a mixture of syn-anti-isomers) (17.4 g) and thiourea (5.4 g) in ethanol (100 ml) is refluxed for 4 hours. The reaction mixture is left in the refrigerator until precipitation
    crystals. The crystals are filtered, ethanol is drunk and dried. Ethyl 2-methoxyimino-2- (2-aminothiazol-4-yl) acetate, bromohydrate (anti-isomer) (9.5 g) is obtained. The filtrate and washings are combined and concentrated under reduced pressure. 100 ml of water are added to the residue and the mixture is washed with ether. Then the aqueous layer is alkalinized with 28% aqueous ammonium solution and extracted with ethyl acetate. The extract is washed with water and with a saturated aqueous solution of sodium chloride and dried over magnesium sulphate. The solvent is distilled off under reduced pressure. Ethyl 2-methoxyimino-2- (2-aminothiazol-4-yl) acetate crystals (syn-isomer) are obtained, which can be represented as ethyl 2-methoxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl ) aceate (syn-isomer) (5.2 g).
    B. 10 ml of ethanol is added to a suspension of ethyl 2-methoxyimino-2- (2 aminothiaol-4-yl) acetate (syn-isomer), which can be represented as ethyl 2-methoxyimino-2- (2-imino-2,3 -dihydrothiazol-4-yl) acetate 1-isomer) (2.2 g) in 1 n. aqueous solution of sodium hydroxide (12 ml), the mixture is stirred for 15 h at ambient temperature. The reaction mixture was adjusted to pH 7.0 with 10% hydrochloric acid and ethanol was distilled off under reduced pressure. The resulting aqueous solution was washed with ethyl acetate, the pH of the solution was adjusted to 2.8 with 10% hydrochloric acid and stirred while cooling with ice to precipitate crystals. The crystals are isolated by filtration, washed with acetone and recrystallized from ethanol. Colorless needle-like crystals of 2-matoxyimino-2- (2-aminothiazol-4-yl) acetic acid (syn-isomer) are obtained, which can be represented as 2-meGOxyimino-2- (2-imino-2,3-dihydrothiazole-4- or) acetic acid (syn-isomer) (1.1 g).
    Example 6. 5 ml of pyridine is added to a suspension of 2-methoxyimino-2- (2-aminothiazol-4-yl) acetic acid (syn-isomer), which can be represented as 2-methoxy-amino-2- (2-imino-2, 3 α-dihydrothiazol-4-yl) acetic acid (syn-isomer) (2.0 g) in ethyl acetate (20 ml). A solution of 2,2,2-trifluoroacetic anhydride {2.5 g) in ethyl acetate (3 ml) is added dropwise to it, stirred at 5-7 ° C, and the resulting mixture is stirred for 30 minutes at 3-5 ° C. 30 ml of water are added to the reaction mixture and the ethyl acetate layer is separated. The mixture is extracted into ethyl acetate with ethyl acetate, the ethyl acetate layers are combined together, washed with water and with a saturated aqueous solution of sodium chloride and dried over magnesium sulfate. The solvent is distilled off under reduced pressure to obtain 2-methoxyimino-2- (2,2,2-trifluoroacetylamino) thiazol-4-yl) acetic acid (syn-isomer), which can be represented as 2-methoxyimino-2- (2 , 2,2-trifluoroacetylamino-2,3-dihydrothiazap-4-yl) acetic acid (syn-isomer) (0.72 g).
    IR (nujol): 1725, 1596
    2-methoxyimino-2- (2-formylaminothiazol-4-yl) acetic acid (syn-isomer), which can be represented as 2-methoxyimino-2- (2-FORMILIMINO-2, 3-dihydrothiazol-4-yl) acetic acid (syn-isomer) so pl. 152С (with decomposition).
    Getting the target products.
    Example 1. Phosphorus oxychloride (1.13 g) is added dropwise to dimethylformamide (0.54 g) while stirring and cooling with ice, and the resulting mixture is continued to be stirred for 30 minutes at 40 ° C, and then added to it dried ethyl acetate (13 ml). To the mixture is gradually added 2-methoxyimino-2- (2-trifluoroacetylaminothiazol-4-yl) acetic acid (syn-isomer, which can be represented as 2-methoxyimino-2- (2-trifetropatsettilamino-2 | Z-dihydrothiazole-4- dl) acetic acid (syn-isomer) (2.0 g) with cooling from 3 to 5 ° C, and the resulting mixture is stirred at this same temperature for 40 minutes. The solution thus obtained / is added to the solution, which is obtained by stirring a mixture of 2-methyl-7-amino-3-cephem-4-carboxylic acid (1.44 g) and trimethylsilylacetamide (9.78 g) in dried ethyl acetate (30 ml) .510 min at 35–4O s, while cooling to -25 to -20 ° C with stirring. The resulting mixture is stirred for 1 hour at the same temperature, then cold water is added to it, and the mixture is stirred for 5 minutes at ice at the same temperature while cooling with ice. the mixture and the remaining aqueous layer was extracted with ethyl acetate (20 ml x 2). The ethyl acetate layer was combined, washed with water and then 50 ml of water was added thereto, the mixture was adjusted to pH 7.5 with a saturated aqueous solution of sodium bicarbonate while cooling with ice and stirring are separated odny layer. After washing the aqueous layer with ethyl acetate, another 70 ml of ethyl acetate is added to it, the pH of the mixture is adjusted to 2.5 with 10% hydrochloric acid under ice-cooling and stirring. A layer of ethyl acetate was separated from the mixture, and the remaining aqueous layer was extracted with ethyl acetate (30 ml). The ethyl acetate layers are combined, washed with an aqueous solution of sodium chloride, dried and then concentrated until the total volume reaches about 10 ml. Diethyl ether (20 ml) is added to the residue and the mixture is stirred for about 1 hour. The precipitated part is filtered, washed with diethyl ether, dried and taken up to give 2-methyl-7-2-methoxyimino-2- (trifluoroacetyl-aminothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-methyl-7-2-methoxyimino-2- (2-trifluoroacetylimino-2, 3-dihydrothiazol-4-yl) acvtamido J-3 -cephem-4-carboxylic acid (strength-isomer) (2.2 g), T.PL.197198c (with decomposition). The remaining filtrate is concentrated, the residue is washed with diethyl ether and dried. Another 0.3 g of the desired compound is obtained.
    Example 2. To 78 ml of dimethylformamide, phosphorus oxychloride (11.9 g) is added dropwise with stirring and ice-cooling, and the mixture is stirred for 30 minutes at 40 ° C. 2- (2-formylaminothiazol-4-yl) -glyoxylic acid is added to the mixture, which can be represented as 2- (2-formylimino-2,3-dihydrothiaol-4-yl) -glyoxylic acid (7.8 g) at cooling to and then the mixture is stirred for 30 minutes while cooling to a temperature of from -20 to the mixture thus obtained is added to the solution, which is prepared with stirring of 2-methyl-7-amino-3-cephem-4-carboxylic acid (8, 35 g) and bio- {trimethylsilyl acetamide (19.5 ml) in dry methylene chloride (170 ml) at room temperature, while cooling to -50 to with stirring. The mixture was stirred for 1 hour at -fc from -45 to -40 ° C, and then the reaction mixture was poured into a solution of sodium bicarbonate (32 g) in water (1.5 l) with shaking. The aqueous layer was isolated and washed with ethyl acetate. The aqueous solution is layered with ethyl acetate and the pH is then adjusted from 1 to 2 with concentrated hydrochloric acid. The ethyl acetate layer was separated from the mixture, and the remaining aqueous layer was extracted with ethyl acetate (200 mlx2). The ethyl acetate layers were combined, washed with water and then concentrated to a small volume. The precipitate is isolated by filtration, washed with a small amount of ethyl acetate and then dried. Get 2-methyl-7-G2- (2-formylsi1-isothiazol-4-yl) glyoxylamine-3-cef m-4-carboxylic acid, which can be represented as 2-methyl-7-2- (2-FORMILMINO-2, 3-dihydrothiazol-4-yl) glyoxylamido-3-cephem-4-carboxylic acid (7.9 g), mp 210-215 s (with decomposition).
    Example 3. To a solution of chloride ionic ion (3.01 g) in methylene chloride (45 ml) was added methyl formamide (0.928 g) and 2- (2-formylaminothiazol-4-yl) glyoxylic acid, which can be represented as 2- (2-formylimino-2, 3-dihydrothiazol-4-i) glyoxylic acid (3.71 g) according to ocher-; di, and the mixture is stirred at room temperature for 4 hours. The resulting mixture is added in 5 minutes to the solution, which is obtained by stirring a mixture of 2-methyl-7-amino-3-cephem-4-carboxylic acid (3.3 g) and trimethylsilyl acetamide (16.2 g) in methylene chloride (60 ml) at room temperature for 40 min and stirred while cooling to -25 - -20 ° C. The mixture is stirred for 30 minutes at a temperature of from -25 to -20C, 30 minutes at a temperature of from -10 to, and then 30 No. 1H at room temperature. A saturated aqueous solution of sodium bicarbonate is then added to the reaction mixture. in order to dissolve the precipitate, and isolate the aqueous layer. Ethyl acetate was added to the aqueous layer, the pH of the mixture was adjusted to 2 with 2N. hydrochloric acid and a layer of ethyl acetate are separated. The remaining aqueous layer was extracted again with ethyl acetate. Combine the ethyl acetate layers, wash with saturated aqueous sodium chloride solution, 5 dry over magnesium sulfate and concentrate. The resulting crystalline residue is pulverized in diethyl ether, isolated by filtration and dried. A yellow crystalline powder of 2-methyl-7-G2- (2-formylaminothiazol-4-yl) glyoxylamins-3-cephem-4-carboxylic acid is obtained, which is ALWAYS presented as 2-methyl-7-G2- (2-formyl-amino- 2, 3-dihydrothiazol-4-i) gly5 oxylamido 3-cephem-4-carboxylic acid (3.81 g).
    I IR spectrum (in nujol): 3475, 3315. 3200, 1788, 1655, 1620, 1530, 1240, 1185 cm-.
    0 EXAMPLE 4. To 6.42 g of dimethylformamide, phosphorus oxychloride (12.5 g) is added dropwise over 20 minutes while stirring and cooling to 5-10 ° C. The resulting mixture is stirred for 30 min.
    g at 40 ° C, then ethyl acetate (200 MP) is added with vigorous stirring. After the mixture is cooled to 3 ° C, 2-methoxyimino-2- (2-formylaminothiazol-4-yl) acetic acid (syn-isomer) is added to it, which can be represented as 2-methoxyimino-2- (2 α-formyl-amino-2,3-dihydrothiazol-4-yl) acetic acid (sio-isomer) (16.34 g), and then the mixture is over-. stir 40 min at 3-5 ° C. The resulting solution is added to a solution obtained by stirring a mixture of 2-methyl-7-amino-3-cephem-4-carboxylic acid (tl7, l g) and trimethylsilylacetamide (84 g) in ethyl acetate (7-00 ml)
    for 1 h at room temperature with vigorous stirring and cooling to. The mixture is stirred for 1 h at t -20 to -15 s and 30 min at t from -10 to-5 ° C to this
    water (200 mp) is added from the mixture at room temperature, and then stirred for another 20 minutes at the same temperature. Thereafter, a saturated aqueous solution of bicarbonate "at" is added to the mixture in order to dissolve the precipitate, and the aqueous layer is added. Ethyl acetate is added to the aqueous layer, the pH of the mixture is adjusted to 2 with 2N. hydrochloric acid, and then the ethyl acetate layer is separated. The remaining aqueous layer was extracted again with ethyl acetate. The ethyl acetate layers were combined together, washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, treated with activated charcoal and concentrated. 5 t. The resulting crystalline residue is sprayed into diethyl ether, filtered by filtration and then dried. White crystals of 2 mvtil-7-2-methoxyimino-2- (2-formylamino-thiaool-4-yl) acetamido-3-cephem-4-carboxylic acid are obtained; this can be represented as 2-methyl-7-G2-methoxyimimo -2- (formylimino-2, 3-dihydrothiazol-4-yl) acetamido} -3-cephem-4-carboxylic acid (sinisomer) (32.2 g). This compound is recrystallized from methanol. White crystals of the pure title compound are obtained, m.p. 174-200 ° C (with decomposition). The following compounds are prepared analogously. 1.2-Methyl-7-G2-hydroxy-2- (2-c№1INO and azol-4-yl) acetamido-3-cephem-4-ka-boic acid hydrochloride, which can be represented as 2-methyl-7-2 hydrochloride OXI-2- (2-imino-2,3-dihydrothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid, m.p. 250 ° C 2.2-Methyl-7-G2-methoxyimino-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-methyl- 7- 2-methoxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl) acetamido} -3-cephem-4-carboxylic acid (synisomer), condensation temperature 241 ° C. 3. 2-methyl-7-f2- (2-am notiazol-4-yl) glyoxylamino-j-3-cefem-4-carboxylic acid chlorohydrate, which can be represented as 2-methyl-7- 2- (2-imino-hydrochloride) 2,3-dihydrothiazol-4-yl) glyoxylamido} -3-cephem4-carboxylic acid, m.p. 70s 4.2,2,2-Trichloroethyl 2-methyl-7-P2-methoxyimino-2- (2-aminothiazol-4-yl) acetamido} -3-cephem-4-carboxylate (syn-isomer), which can be represented as 2 2,2-trichloroethyl-2-methyl-7-2-methoxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl) acetamido} -3-cephem-4-carboxylate (syn-isomer), m.p. 125-149 ° С (with decomposition). 5. Pivaloyloxymethyl 2-methyl-7- 2-methoxyimino-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4-carboxy-lat (syn-isomer), which can be represented as Pivaloyloxymethyl 2-methyl- 7- 2-methoxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl) acetamido 1 -3-cephem-4-carboxyl, at (syn-isomer), mp. 165-170 ° C (with decomposition). 6.p-nitrobenzyl 2-methyl-7-f2-oxyimino-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4-carboxylate (si issemer), which can be represented as p-nitrobenzyl-2- methyl 7-C2-OXY imino-2- (2-imino-2,3-dihydrothiazol-4-yl) acetamido-3-C-cephem-4-carboxy-lat (syn-isomer), powder. IR (nujol): 3400, 328 3200, 1770, 1710, 1700, 1650, 1620 7.2-Methyl-7-G2-oxyimino-2- (2-amine-.thiazol-4-yl) acetamido -3- Cephe-4-kag, boic acid (syn-isomer), can be prefilled as 2-methyl-7-2-oxyimino-2- (2-imino-2,3-dihydro-thiazol-4-yl) acetamido7-3- cephem-4-carboxylic acid (syn-isomer IR spectrum (in nujol): 3250,1765, 1625 cm 8.2-Methyl-7-G2-ztoksiamino-2- (2-formylaminothiazol-4-yl) acetamido} -3- cephem-4-carboxylic acid (sinisomer, which can be represented as 2-methyl-7-G2-ethoxyamino-2- (2-formylimino-2, 3-dihydrothiazol-4-yl) acetamido} -Z-cephem-4-carboxylic acid (syn-of measures). 9.2-Methyl-7- 2-isopropoxyimino-2- (2-formylaminothiazol-4-yl) acetamido} -3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-methyl-7 -G2-isopropoxyimino-2- (2-formylimino-2,3-dihydrothiazol-4-yl) -acetamido} -3-cephem-4-carboxylic acid (syn-isomer). IR spectrum- (in Nujol): 3480 , 3300, 3180, 1780, 1740, 1700, 1660 cm. 10. 2-Methyl-7-f2-3TOH hydroimide-2- (2-aminothiazol-4-yl) acetamido} -Z-cephem-4-carboxylic acid hydrochloride syn -isomer), which can be represented as 2-methyl-7-G2-ethoxyimino-2- (2-imino-2,3-dihydrothiazol-4-yl) acetamido} -3-cephem-4-carbohydrochloride oic acid (syn isomer). IR spectrum (nujolb: 3350, 1790, 1730, 1670, 1630 cm-g 11.2-Methyl-7-G2-ISOPROPOXYImino-2- (2-aminothiazol-4-yl) acetamido} -Z-cephem-4-carboxylic acid (synisomer), which can be represented as 2-methyl-7-C2-isopropoxyimino-2- (2-imino-2,3-dihydrothiazol-4-yl) acetamido} -3-cephem-4-carboxylic acid (syn- isomer. IR spectrum (in nujol): 3350, 1780, 1670, 1600 cm -, - 12.2-Methyl-7-2-propoxyimino-2- (: -formylaminothiazol-4-yl) acetamido} -3-cephem -4-carboxylic acid (synisomer), which can be represented as 2-methyl-7-C2-propoxyimino-2- (2-formylimino-2, 3-dihydro-thiazol-4-yl) acetamide 3-cephem-4-carb new acid (syn-isomer). IR spectrum (in nujol): 3450, 3300, 3050, 1780, 1730, 169СЬЬ, 1660 cm - 13.2-Methyl-7-G2-PROPOXIIMINO-2- (2-amyothiazol-4- yl) acetamido2-3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-methyl-7-G2-propoxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl) acet amido} -Z-cephem-4-carboxylic acid (sinisomer). IR spectrum (in nujol): 3330, 3080, 1780, 1670 CNTl 14.2-Methyl-7-2-hexyloxyimino-2- (2-ak 1NOTiazol-4 -yl) acetamido} -3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-methyl-7-2-g; exyloxyimino-2- (2-imino-2, 3-dihydrothiazol-4 -il) acet Medo -s-cephem-4-carboxylic acid (syn isomer).
    IR (nujol): 3300.3200, 1780, 1670, 1630 cm
    15.2-Methyl-7- 2-hexyloxyimino-2- (2-formylaminothiazol-4-yl) acetamido D-3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-methyl-7- 2- hexyloxyimino-2- (2-FORMILIMINO-2.3-dihydrothiazol-4-yl) acetamido3-3-cephem-4-carboxylic acid (syn-isomer).
    IR (nujol): 3270.3180, 1790, 1700, 1655 CM-I
    16. Hexanoyloxymethyl 2-methyl-7-G2-hexyloxyimino-2- (2-aminothiazol-4-yl) acetamido3-3-cephem-4-carboxylate (syn-isomer), which can be represented as Hexanoylmethyl 2-methyl-7- 2-hexyloxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl) acetamidoT-3-cephem-4-carboxylate (syn-isomer). IR (nujol): 3340.3200 (wide bands), 3150 (wide bands), 1790 (wide bands), 17501790, 1680, 1630 cm-1
    17.2-Methyl-7- 2-butoxyimino-2- (2-aminothiazol-4-yl) acetamido} -3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-methylC2-butoxyimino-2 - (2-imino-2, 3-dihydrothiazol-4-yl) acetamido 3 -3-C-cephem-4-carboxylic acid (sinisomer).
    18.2-Methyl-7- 2-isobutoxyimino-2- (2-aminothiazol-4- and 1) acetamidoJ-3-cephem-4-carboxylic acid (syn-isomer), which can be represented as .2-methyl-7-2 β-isobutoxyimino-2- (2-imino-2, 3-dihydro-thiazol-4-yl) acetamido -Z-cephem-4-carboxylic acid (syn-isomer),
    Example 5. Suspension of 2-methoxyimino-2- (2-aminothiazol-4-yl) acetic acid (syn-isomer), which can be represented as 2-methoxyimino-2- (2-imino-2, H-dihydrothiazole-4- (dl) acetic acid isine isomer) 26 g in 250 ml of ethyl acetate is cooled before and 25 g of phosphorus oxychloride is added dropwise to it, stirred under ice-cooling, and then the mixture is stirred for 30 minutes at. To the mixture is added dropwise a solution of trimethylsilane-acetamide (22 g; in 20 ml of ethyl acetate with stirring and ice-cooling. The resulting mixture is stirred for 30 minutes at 4-6 ° C and then an additional 25 g of phosphorus oxychloride is added with stirring and cooling with ice. The resulting the mixture is stirred for 40 minutes at the same temperature and then 10.6 g of dimethylformamide is added dropwise to it at the same temperature. The mixture is changed for 40 minutes at the same temperature and the resulting clear solution is cooled to. To a solution of 2-methyl-7- amino-3-cephem-4-carboxylic acid
    (23.9 g) in a solution of sodium bicarbonate (25 g) and water (400 ml) was added acetone (300 ml) and the mixture was cooled to -5 ° C. To the mixture is added dropwise a previously obtained f clear solution at a temperature of from -5 to, and then the mixture is stirred for 2 hours, all this time the pH of the solution is maintained at 6 s using an aqueous solution of bicarbonate
    0 sodium ./ The undissolved substances are filtered and the aqueous layer is separated. The pH of the aqueous layer was adjusted to 3 with 20% hydrochloric acid, and the precipitated crystals were crystallized by filtration, washed with water and acetone over
    5 turns and then dried under the pressure. Get 2-methyl-7- 2-methoxyimio-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-methyl-7- 2- methoxyimino-2 (2-IMINO-2, 3-dihydrothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid (syn-isomer) (39.4 g). This compound is identical to the compound obtained in S-6 in Example 6, by definition, using IR and NMR spectroscopy.
    The physical properties of the sodium and ammonium salts of this compound are given below.
    Q 1. Sodium salt, powder.
    IR spectrum (Nujoled: 1770, 1660, 1560, 1500 cm
    NMR spectrum (dfe -dimethyl sulfoxide, 1.37 3H, d, J 7 Hz), 3.64
    . (1H, m), 3.84 (ZN, s), 4.97 (lH, d J
      5.0 Hz), 5.74 (1H, m), 6.21 (lH, d, J 6.0 HzJ, 6.70 (1H, s), 7.30
    (2H, m), 9-, 63 (1H, m).
    2. Ammonium salt, powder. IR spectrum IB nudzhole): 1775.1660.0 1580, 1530 cm-1
    NMR spectrum (d-dimethyl sulfoxide, #): 1.37 (3H, d, J 7.0 Hz), 3.64 IIH.M), 3.83 (ZN, s), 4.99 (lH, d, J 5.0 Hz), 5.8 15H, m). 6.17 (lH, d, 5.J 6.0 Hz), 6.87 (1H, s), 7.27 12H, m),
    9.55 (1H, 1).
    Example 6. To a solution of sodium acetate (11.6 g) in water (43 ml) was added 2-methyl-7-2-methoxyiminoQ -2- (2-trifluoroacetylaminothiazol-4-yl) acetamido) -3-cephem-4 -carbon fiber. slot (syn-isomer), which can be represented as 2-methyl-7-T2-methoxyimino-2- (2-trifluoroacetylimino-2,3-dihydro-thiazol-4-yl) acetamido-3-cephem-45-carboxylic acid (syn -isomer) (2.1 g) with stirring, and adjusting the pH of the mixture to an equal 6.5% aqueous solution of sodium bicarbonate. The resulting mixture is stirred for
    权利要求:
    Claims (2)
    [1]
    0 nights at room temperature. After completion of the reaction, the pH of the reaction mixture is adjusted to 2.8-3 with 10% hydrochloric acid, and then cooled. The precipitate was isolated by filtration, dry and to give 2-methyl-7-G2-methoxyimino-2-12-aminothiazol-4-yl) acetamido-3-cephem-4 carboxylic acid {syn-isomer; which can be represented as 2- methyl-7-H2-methoxyimido-2- (2-IMINO-2, 3-dihydro-thiazol-4-yl) acetamido-3-cephem-4-carboxylic acid (syn-isomer) (1,1 r), t condensation 7 241 C. The same target compound (0.25 g) is obtained additionally from the filtrate. Example 7. To a suspension of 2-me, Thyl-7-G2- (2-formylaminothiazol-4-yl-Uglyoxylamidr-3-cephem-4-carboxylic acid, which can be represented as 2-methyl-7-2- (2-formyl-meyno-2 , 3-dihydrothiazol-4-yl) glyoxylamidr -3-cephem-4-carboxylic acid (3.0 g in methanol (60 ml) was added but a drop of phosphorus oxychloride (2.55 g) while cooling with ice and stirring, the mixture was stirred for 3.5 hours at the same temperature and then for 30 minutes at room temperature.After the reaction was completed, the reaction mixture was poured into diethyl ether (400 ml), the precipitate was filtered off and washed ethyl ester and then dried. 2-Methyl-7-G2- {2-aminothiazol-4-yl) glyoxylamido-3-u-hydrochloride is prepared; epheme-4-carboxylic acid, which can be represented as 2-methyl hydrochloride 2-methyl - (2-imino-2, 3-digi-rothiazol-4-yl) glyoxyl-3-C-cephem-4-carboxylic acid (2.2 g), mp 270 ° C. Example 8. To a suspension of 2-methyl -7-2-methoxyimino-2- (2-formyl aminothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-meTyl-7- (2-methoxyimino- 2- (2-formylimo-2, 3-dihydrothiazol-4-yl) -acetamido) -3-cephem-4-carboxylic acid (syn-isomer) (g) in methano e (90 ml) was added concentrated hydrochloric acid (2.12 ml) with stirring at room temperature and the resulting mixture was stirred at the same temperature. Diethyl ether is gradually added to the reaction mixture until precipitation of crystals begins. The mixture is left for 30 minutes, the precipitated crystals are filtered, washed with diethyl ether, dried, and white crystals of 2-methyl-7-2-methoxyimino-2- (2-aminothiazol-4 yl) acetamido-2-cephem-4 are obtained. -carboxylic acid (syn-isomer), which can be represented as 2-methyl-7-G2-methoxyimio-2- (2-IMINO-2, 3-dihydro-thiazol-4-yl-U-acetamido-D-3-cephem-4-carboxylic hydrochloride acids syn-isomer) (7.9 g). The remaining filtrate is concentrated to half the volume, diethyl ether is gradually added to the concentrated filtrate until precipitation begins, and the mixture is left for an hour. The crystals are filtered, washed with diethyl ether and dried. Obtain an additional amount of the target compound (0.5 g). IR (nujol): 3300, 3295, -1780, 1720, 1660, 1630, 1300 / K suspension of 2-methyl-7-2-methoxyimino-2- (2-aminothiazol-4-IL) acetamido hydrochloride - 3-cephem-4-carboxylic acid (syn-isomer). Which can be represented as 2-methyl-7-H2-methoxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl) acetamide-J- hydrochloride 3-cephem-4-carboxylic acid (synisomer; (7/7 g) in water (77 ml) was added with a saturated aqueous solution of sodium bicarbonate (44 ml), the pH of the solution thus obtained was set to 3.1. N. hydrochloric acid and left for 1 h in a cold place. The precipitated crystals precipitate a fil It is washed with water and dried to give a white powder of 2-methyl-7-C2-methoxyimino-2- (2-aminothiazol-4-yl) adetamido J-3-cepheme-4-carboxylic acid (syn-isomer), which can be represented as 2-methyl-7- 2-methoxyimino-2- (2-IMINO-2,3-dihydrothiazol-4-ylJ acetamido-3-cephem-4-carboxylic acid (syn-isomer) (6.67 g), t mp 196-240 ° C (with decomposition}. Anshopically obtain the following compound. 1. 2-methyl-7g-G2-OXI-2- (2-aminothiazol-4-yl) acetamido} -3-cephem-4-carboxylic acid hydrochloride, which can be represented as 2-methyl-7-t2-OKCH hydrochloride -2- (2-imino-2,3-dihydrothiazol-4-yl) acetamido - 3-cephem-4-carboxylic acid, mp. 250 ° C. 2.2,2,2-Trichloroethyl 2-methyl-7-G2-methoxyimino-2-2-aminothiazol-4-yl) acetamide q3 -Z-cephem-4-carboxylate (syn-isomer), which can be represented as 2-trichloroethyl 2-methyl-7-2-methoxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl; acetamid-L-3-cephem-4-carboxylate (syn-isomer), mp 128-149 ( with decomposition. 3.2,2,2-Trichloroethyl 2-methyl-7- 2-oxyimino-2- (2-ad-1-thiazol-4-yl) acetamido} -3-cephem-4-carboxylate (syn-isomer), which can Present as 2,2,2-Trichloroethyl 2-methyl-7-G2-6ximimino-2- (2-imiko-2,3-dihydrothiazol-4-yl) acetamido-3-cephem-4-carboxylate (syn-isomer) , so pl.175-178 C (with decomposition). 4 .pgNitrobenzyl 2-methyl-7-2-oxyimino-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4-carboxylate, which can be represented as p-nitrobenzyl 2-methyl-7-Gs-oxyimino -2- (2-IMINO-2,3-dihydrothiazol-4-yl) acetamido21-3-cephem-4-carboxylate (syn-isomer), powder. IR spectrum (nujol): 3400.3280, 3200, 1770 , 171Qj 1700, 1650, 1620 s; m. 5.2-Methyl-7-p-oximemino-2- (2-aminothiazol-4-yl) acetamide qJ-3-cephem-4-carboxylic acid {syn-isomer) which can be presented as 2-methyl-7-G2-OXIIMINO-2- (2-imino-2,3-dihydrothiazol-4-yl) acetamide-3-cephem-4-carboxylic acid. (synisomer). IR spectrum (in nujol): 3250, 1765 1625 cm-1 6.2-Methyl-7-C2-ethoxyimino-2- {2-aminothiazol-4-yl) acetamide q -3-cefvm-4-carboxylic acid CHLORGILRATE (syn- isomer), which can be represented as 2-methyl-7-G2-ethoxyimino-2- (2-imino-2,3-dihydrothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid chlorohydroate (syn-isomer ). IR spectrum (in nujol): 3350, 1790 1730, 1670, 1630 cmH 7.2-methyl-7-G2-IZOPROPOXYIMINO-2- (2-aminothiazol-4-yl) acetamido3-3-cephem-4-carboxylic acid (sine iiomer), which can be represented as 2-methyl-7- (2-isopropoxyimino-2- (1.2-ymino-2,3-dihydrothiazol-4-yl) acetamido-3-cePem-4-carboxylic acid (syn -Isomer. LC spectrum (in nojol): 3350, 1780 1670 1600 8.2-Methyl-7-2-propoxy-2-(2-aminothiazol-4-yl) acetamido3-Z-3-cephem-4-carboxylic acid { Sniper meter), which can be represented as 2-methyl-7-2-propoxyimiao-2- (2-YMINO-2,3-dihydrothiazol-4-Il) acetamido-3-cephem-4-carbonones acid {syn isomer) .. IR (in nujol): 3330, 3080 1780, 1670 cm-. 9.2-Methyl-7- 2-butoxyimino-2- {2-aminothiazol-4-yl) aietamido3 -3-cephem-4-carboxylic acid (syn-isomer) I which can be represented as 2-methyl-7- {2 -butoxyg®1NO-2- (2-IMINO-2, 3-dihydrothiazol-4-yl) acetamido-3-cce (|) em-4-carboxylic acid (syn-isomer). IR spectrum (in nujol): 3300. 32DO, 1780, 1670. 1630 cm. 10.2-Methyl-7-G2-isobutoxiums of o-2- (2-aminothiazol-4-yl) acetamido} -3-cephem-4- carboxylic acid (synisomer). which can be represented as 2-methyl-7-2-isobutoxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl) acetamido3 3-ceFem-4-carboxylic acid (syn-isomer). IR (nujol): 3340.3200 (wide lines), 3150 (wide lines), 1790 (wide lines), 17501790, 1680, 1630. Example 9. To a solution of 2,2,2-trichloroethyl 2-methyl-7-G2-methoxin et-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4-carboxylate (syn-isyl-mer) t which can be represented as 2.2,2-trichloroethyl 2-methyl-7-2-m "toxyimino-r2- (2-imino-2,3-dihydro-thiazol-4-yl) acetamido} -3-cPhem-4-carboxylate (syn -isomeo) (OD g) in tetoagidofuran (2 ml) and glacial acetic acid (0.25 mp) were added zinc powder (0.1 g) all at once while stirring and maintaining the temperature below in an ice bath, and then stirred for 1 h at room temperature. More zinc powder (0.1 g) was added to the reaction mixture and the mixture was stirred for 1 hour at the same temperature. The reaction mixture is filtered and the insoluble matter is washed with a small amount of tetrahydrofuran. After the filtrate is washed, the washings are combined and the solvent is distilled off, 5% aqueous sodium bicarbonate solution and ethyl acetate are added to the residue, the pH of the aqueous layer is set to 7 to 8, the mixture is filtered, and then the mixture is separated. are water layer. The pH of the aqueous layer is set equal to 2-3 2 N. hydrochloric acid and then slightly concentrated. The resulting aqueous layers were introduced into a chromatographic column (sloped adsorption resin. Diaion HP 20, manufactured by Mitsubishi Chemical Industries), and the column was washed with water, eluted with 20% and then 40% methanol. The eluates containing the desired compound are combined and lyophilized. A white powder of 2-methyl-2-methoxyimino-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid (syn-isrmer) is obtained, which can be represented as 2-methyl-7-T2- methoxyimino-2- (2-IMINO-2, 3-dihydro-thiazol-4-yl) acetamido3-3-cephem-4-carboxylic acid (syn-isomer) 0.015 g). 230-235 C (with decomposition), Similarly, receive: 1.2-Methyl-7-G2-methoxyimino-2- (2-formylaminothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid (synisomer), which can be represented as 2-methyl-7-t2-methoxyimino-2- (2-formyl in no-2, 3-dihydrothiazol-4-yl) acetamido D-3-cephem-4-carboxylic acid Csin-iznler) so pl. 174-204 ° С (with decomposition).
    [2]
    2. 2-methyl-7-G2-hydroxy-2- (2-aminothiazol-4-yl) acetamide-3-cephem-4-carboxylic acid hydrochloride, which can be reasonably presented as 2-methyl-7-G2-hydroxy hydrochloride (2-IMINO-2,3-dihydrothiazol-4-yl acetamido-3-cephem-4-carboxylic acid, mp. 250 C. 3.2-Methyl-7-C2-oxyimino-2 - (2-amino-thiazol-4-yl ) acetamide-3-cephem-4-carboxylic acid; Chinsin-isomer), which can be represented as 2-methyl-7-2-oxy1 in 1HLAO-2- (2-imino-2,3-dgnidrotiazol-4-l) acetamido - 3-cephem-4-carboxylic acid (synomer). IR (nujol): 3250, 1765, 1625. 4.2-Methyl-7-G2-ETOXYMINO-2- (2-formylaminothiazol-4-yl) acetamido1-3-cephem-4-carboxylic acid (syn-isomer, which can be prepared as 2-methyl-7- (2- ETOXIIMINO-2 - (2-formylimino-2, 3-dihydro-thiazol-4-yl) acetamido 3-cephem-4-cage, boonic acid (syn-isomer). IR spectrum (in Nujol): 3350,3240 3190, 1775, 1700, 1650, 1620 cm. 5.2-Methyl-7-G2-isopropoxyimino-2- (2-formylaminothiazol-4-yl) acetamido} 3-cephem-4-carboxylic acid (syn-isomer), which can be as 2-methyl-7- (2-isopropoxies but-2- (2-formylimino-2,3-dihydro-tiaz-4-yl) acetamido-3-cephem-4-carboxylic acid (syn-isomer). IR spectrum (nujol): 3480, 330 3180, 1780, 1740, 1700, 1660 cm. 6.2-Methyl-7-2-ETOXYMINO-2- (2-aminothiazol-4-yl) acetam W-J-3-cephem 4-carboxylic acid hydrochloride (blue 3), which can be represented as 2-methyl-7-G2-ethoxyimino-2- (2-IMINO-2,3-dihydrothiazole-4-yl) acetamido) -3-cephem-4-carbono-OOH Acid hydrochloride {syn-isomer) IR spectrum (in nujol): 3350, 179 1730, 1670, 1630 cm - 7.2-Methyl-7-GZ-isopropoxyimino-2- {2-aminothiazol-4-yl) acetamide J-3 -cephem-4-carboxylic acid (shn-isomer), which can be represented as 2-methyl-7-2-isopropoxyimino-2- (2-IMINO-2, 3-dihydro-thiazol-4-yl) acetamido 3-ceph m-4-carboxylic acid (syn-isomer). IR spectrum {in nujol): 3350,1780 1670, 1600 8.2-Methyl-7-2-propoxyimino-2- (27 formylaminothiazol-4-yl) acetamido3-3-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-methyl-7-3-propoxyimino-2- (2-FORMILIMINO-2,3-dihydrothiazol-4-yl) acetamido} -3-cephem-4-carboxylic acid (syn-isomer). IR spectrum (in nujol): 3450.3300 3050, 1780, 1730, 1690, 1660, 9.2-methyl-7-G2-propoxyimino-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4- carboxylic acid (syn-isomer), which can be represented as 2-methyl-7-C2-propoxyimino-2- (2-imino-2, 3-dihydro-thiazol-4-yl) acetamido-3-cephem-4-carboxylic acid ( synisomer). IR (nujol): 3330.3080, 1780, 1670 cm. 10. 2-Methyl-7-2-hexyloxyimino-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4-carboxylic acid (synisomer), which can be represented as 2-methyl-7-2-hexyloxyimino-2- (2-imino-2, 3-dihydrothiazol-4-yl) acetamido D-3-cc-4-carboxylic acid 1-syn-isomer) , IR spectrum (in nudzhol): ЗЗЫО, 3200; 1780, 1670, 1630 cm. 11. 2-Methyl-7-f2-hexyloxyimino-2- (2-formylaminothiazol-4-yl) acetamido3-3-cephem-4-carboxylic acid (synisomer), which can be represented as 2-methyl-7-G2-hexyloxyimino -2- (2-formylimino-2,3-dihydrothiazol-4-yl) acetamido J -Z-cephem-4-carboxylic acid (syn-isomer). IR (nujol): 3270, 3180, 1790, 1700, 1655. Example 10. To a suspension of 2-methyl-7- {2-methoxyimino-2- (2-aminothiazol-4-yl) acetamido}-cephem-4-carboxylic acid (syn-isomer), which can be represented as 2-metsh1- 7-G2-methoxyimino-2- (2-IMINO-2,3-dihydrothiazol-4-yl) acetamido} -3-cefvm-4-carboxylic acid (syn-isomer) (4.8 g) in water (48 ml 1N aqueous solution of sodium hydroxide was added dropwise at such a rate that the pH of the mixture remained above 7. The mixture was filtered and lyophilized. A 2-methyl-7-G2-methoxyimino-2- (2-aminothiazol-4-yl) acetamido-3 sodium cephem-4-carboxylate, (syn-isomer) is obtained, which can be represented as 2-methyl-7-Gmethoxyimino- 2- (2-imino-2, 3-dihydrothiazol-4-yl) acetamido-S-cephem-4-sodium carboxylate (syn; isomer) (4.8 g), m.p. 250s This compound is suspended in dry dimethylformamide (20 ml) and pivalate iodomethyl (2.30 g) is added to the suspension with vigorous stirring and cooling to 3-5 sec, and then the mixture is stirred for 20 min at the same temperature. The reaction mixture was poured into a mixture of ethyl acetate (60 ml) and ice-water (10 ml) and shaken. The ethyl acetate layer was separated, washed with a saturated sodium bicarbonate solution, water, and again with a saturated sodium bicarbonate solution. Thereafter, the ethyl acetate layer is dried over magnesium sulfate and the ethyl acetate is distilled off under reduced pressure. The remaining oil is sprayed into diethyl ether (25 ml), filtered and after drying, pivaloxyloxymethyl 2-methyl-7-G2-methoxyimino-o2- (2-aminothiazole is obtained) -4-yl) acetamidoZ-3-cephem-4-carboxylate (syn-isomer), which can be thought of as pivaloyloxymethyl 2-methyl-7-2-methoxyimino-2- (2-imino-2, 3-dihydrothiazole-4 -yl) acetamido-3-cephem-4-carboxylate (syn-isomer) (1.44 g), m.p. 165-170 ° С (with decomposition). Hexanoyloxymethyl 2-me1: yl-7-f2-hexyloxy-imino-2- (2-aminothiazol-4-yl) acetamido-3-cephem-4-carboxylate (syn-isomer), which can be represented as hexanoyl-oximethyl 2-methyl-3 7-G2-hexyloxyimino-2- (2-imino-2,3-dihydrothiazol-4-yl) acetamido D-3-cephem-4-carboxylate (syn-isomer). IR spectrum (in nujol): 3340.3200 (wide bands), 3150 (wide bands), 1790 (wide bands), 1750-179 1680, 1630 cm. Invention Formula: Method for producing derivatives of lower alkyl-7 α-acylamido-3-cephem-4-carboxylic acid of formula I Nif A - iONH-jr Y RHK where fi is methyl or ethyl; R is a hydrogen atom, trihalo (lower) alkyl, lower alkanoyloxy (lower) alkyl or g p-nitrobenzyl; R is a hydrogen atom, a lower alkanoyl or trihalo- (lower alkanoyl; A is carbonyl, hydroxymethylene, synoximinomethylene or syn-lower) alkoxyminomethylene, or in the case of, a hydrogen atom. whether their salts, distinguished by the fact that the compound of the formula P HtN-pY V. ; "Ioou where R and R5 have the above values, or its metallic salt, if RQ is a hydrogen atom, or an acid additive salt, is reacted with a compound of the formula K-gA-eoK BhuAjiJ 1 where A have the above values, or with its metric or acid-aldivite; salt in an organic solvent in the presence of a halogenergic agent at pH 4 to 10 with cooling or at room temperature, and isolate the desired product as a free acid, ester, or salt. Sources of information taken into account in the examination 1. UK patent 1038529, CL.S2A, published 1966.
    类似技术:
    公开号 | 公开日 | 专利标题
    CA1297096C|1992-03-10|Crystalline 7-[2-|-2- hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid |
    DE2727753C2|1987-11-05|
    US4520194A|1985-05-28|Cephalosporins
    JPH0639464B2|1994-05-25|Thiazolyl acetic acid compound
    SU856387A3|1981-08-15|Method of preparing derivatives of 2-lowest alkyl-7-cylamido-3-cephem-4-carboxylic acid or their salts
    DE2805655A1|1978-08-31|NEW CEPHALOSPORANIC ACID DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND THE METHOD FOR THEIR MANUFACTURING
    GB1582295A|1981-01-07|Unsaturated derivatives of 7-acylamido-3-cephem-4-carboxylic acid and process for their preparation
    DE2512670A1|1975-09-25|PROCESS FOR PRODUCING 7BETAACYLAMINO-7ALPHA-ALKOXY-CEPHALOSPORINES OR 6BETA-ACYLAMINO-6ALPHA-ALKOXYPENICILLINES
    EP0264091B1|1992-02-05|3-propenylcephem derivative, preparation thereof, chemical intermediates therein, pharmaceutical composition and use
    SU1005664A3|1983-03-15|Process for preparing derivatives of cephalosporin or their alkali metal salts
    SU867311A3|1981-09-23|Method of preparing d-7-/alpha-|-alpha-4-oxyphenyl)-acetamido/-3-(1-methyltetrazol-5-ylthiometyl-3-cephem-4-carboxalic acid
    JPH09110870A|1997-04-28|Amino-beta-lactam acid salt and its production
    FR2496666A1|1982-06-25|NOVEL CEPHALOSPORINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
    JP3927262B2|2007-06-06|Cephem compound, production method thereof and antibacterial composition
    SU1318144A3|1987-06-15|Method for producing cephalosporin derivatives or salts teherof
    DE2714419C2|1985-12-05|Cephalosporin derivatives, processes for their preparation and pharmaceuticals
    SU814279A3|1981-03-15|Method of preparing 7-/2-oxyimino-2-|-acetamido/-2-methyl-3-cepheme-4-carboxlic acid derivatives in the form of sin-isomers or their salts
    JPH0674276B2|1994-09-21|Novel crystal of 7- [2- | -2-hydroxyiminoacetamido-3-vinyl-3-cephem-4-carboxylic acid |
    SU784780A3|1980-11-30|Method of preparing d-isomers of penicillin derivatives or their pharmaceutically employed salts
    DE2755902A1|1978-06-22|PROCESS FOR THE PRODUCTION OF CEPHALOSPORINES
    JP2567799B2|1996-12-25|Carboxyalkenoic acid and its derivatives
    US4058609A|1977-11-15|7-Dithioacetamido cephalosporins
    US5948774A|1999-09-07|Cephem compounds, their production and use
    DE2818025A1|1978-11-09|METHOD FOR PRODUCING CEPHEM CONNECTIONS
    SU1482532A3|1989-05-23|Method of producing cephem compounds or their physiologically or aharmaceutically acceptable salts
    同族专利:
    公开号 | 公开日
    IE45222B1|1982-07-14|
    CA1117104A|1982-01-26|
    ES470754A1|1979-09-01|
    AU2651977A|1979-01-04|
    US4225707A|1980-09-30|
    ES470755A1|1979-09-01|
    AR218254A1|1980-05-30|
    CA1102307A|1981-06-02|
    JPS5932475B2|1984-08-09|
    SE438337B|1985-04-15|
    OA05688A|1981-05-31|
    CH634074A5|1983-01-14|
    NO772257L|1977-12-29|
    CS196371B2|1980-03-31|
    ES470757A1|1979-02-16|
    HU179181B|1982-09-28|
    ATA449177A|1979-05-15|
    DK284977A|1977-12-29|
    AR221601A1|1981-02-27|
    ES470756A1|1979-09-01|
    ES460083A1|1978-10-01|
    AU512804B2|1980-10-30|
    FR2356654B1|1981-06-19|
    GR68939B|1982-03-29|
    IE45222L|1977-12-28|
    FR2356654A1|1978-01-27|
    CH640539A5|1984-01-13|
    NL7707150A|1977-12-30|
    PT66728B|1978-11-22|
    NZ184493A|1980-03-05|
    PT66728A|1977-07-01|
    FI771866A|1977-12-29|
    JPS535193A|1978-01-18|
    SE7707407L|1977-12-29|
    CH640538A5|1984-01-13|
    AT353963B|1979-12-10|
    DE2728766A1|1978-01-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CH557381A|1967-04-15|1974-12-31|Fujisawa Pharmaceutical Co|PROCESS FOR PRODUCING 3-CEPHEM COMPOUNDS.|
    GB1241656A|1967-08-21|1971-08-04|Glaxo Lab Ltd|Improvements in or relating to cephalosporin compounds|
    GB1279402A|1968-06-14|1972-06-28|Glaxo Lab Ltd|Improvements in or relating to cephalosporin derivatives|
    US3719672A|1968-12-11|1973-03-06|Ciba Geigy Corp|4-substituted methylene-7-amino-8-oxo-5-thia-1-aza-bicyclo(4,2,0 oct-2-ene-2-carboxylic acids|
    GB1445979A|1972-10-25|1976-08-11|Glaxo Lab Ltd|Cephalosporin derivatives|
    JPS5932472B2|1973-03-15|1984-08-09|Fujisawa Pharmaceutical Co|
    AR208283A1|1973-03-15|1976-12-20|Fujisawa Pharmaceutical Co|A PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 2-ALKYL-2-O 3-FEFEM-4-CARBOXYL ACID|
    GB1453049A|1973-08-21|1976-10-20|Glaxo Lab Ltd|Cephalosporing antibiotics|
    JPS50111093A|1974-02-20|1975-09-01|
    NZ176206A|1973-12-25|1978-03-06|Takeda Chemical Industries Ltd|Cephalosporins|
    JPS5512913B2|1974-11-13|1980-04-04|
    JPS5652908B2|1974-07-17|1981-12-15|
    JPS5932473B2|1974-02-20|1984-08-09|Fujisawa Pharmaceutical Co|
    US3928333A|1974-05-20|1975-12-23|Lilly Co Eli|Process for the preparation of 3 cephalosporin esters|
    FR2271828B1|1974-05-24|1980-02-08|Bristol Myers Co|
    FR2286138B1|1974-09-27|1976-12-31|Rhone Poulenc Ind|
    DK154939C|1974-12-19|1989-06-12|Takeda Chemical Industries Ltd|METHOD OF ANALOGUE FOR THE PREPARATION OF THIAZOLYLACETAMIDO-CEPHEM COMPOUNDS OR PHARMACEUTICAL ACCEPTABLE SALTS OR ESTERS THEREOF|
    GB1536281A|1975-06-09|1978-12-20|Takeda Chemical Industries Ltd|Cephem compounds|
    JPS6139952B2|1975-10-03|1986-09-06|Fujisawa Pharmaceutical Co|JPH0142955B2|1978-01-13|1989-09-18|Takeda Chemical Industries Ltd|
    MA18686A1|1978-07-07|1980-10-01|Ciba Geigy Ag|AMINOTHIAZOLIC COMPOUNDS|
    US4305937A|1978-08-17|1981-12-15|Fujisawa Pharmaceutical Co., Ltd.|2-Lower alkyl-7-substituted-2 or 3-cephem-4-carboxylic acid compounds and antibacterial pharmaceutical compositions containing them|
    EP0048504B1|1978-09-12|1988-08-17|Fujisawa Pharmaceutical Co., Ltd.|Intermediate compounds for preparing cephem compounds; processes for their preparation and processes for preparing cephem compounds|
    EP0021688B1|1979-06-07|1983-07-13|Yamanouchi Pharmaceutical Co., Ltd.|7- cephalosporins, their preparation, and pharmaceutical compositions containing them|
    US4443374A|1982-02-01|1984-04-17|E. R. Squibb & Sons, Inc.|Process for preparing -3-[[[imino]-acetyl]amino]-2-oxo-1-azetidinesulfonic acid, and 4-substituted derivatives|
    JPH0352472B2|1982-07-23|1991-08-12|Meiji Seika Kk|
    JPS63107977A|1986-05-21|1988-05-12|Takeda Chem Ind Ltd|Isoxazolone derivative|
    JPH09110877A|1995-10-17|1997-04-28|Katayama Seiyakushiyo:Kk|Cephem compound, its production and antibacterial agent containing the compound|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB26740/76A|GB1580189A|1976-06-28|1976-06-28|Cephalosporin derivatives and the preparation thereof|
    GB26277|1977-01-05|
    [返回顶部]